Yoshiyuki Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshiyuki Kobayashi has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Masao Kobayashi
Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan
17 shared publications- Nobutsune Ishikawa
Department of Pediatrics, Hiroshima University Hospital, Japan; Epilepsy Center, Hiroshima University Hospital, Japan
11 shared publications Yuji Fujii
Department of Pediatrics, Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan
10 shared publicationsNobutsune Ishikawa
Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan
6 shared publications- Satoshi Okada
Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
6 shared publications Hiroo Tani
Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan
5 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Acute necrotizing encephalopathy associated with COVID-19 in a pediatric patient and a systematic review
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, can lead to neurological complications such as acute necrotizing encephalopathy (ANE). However, the pathogenesis of ANE associated with COVID-19 remains unclear. We report a case of ANE associated with COVID-19 and then conducted a literature review using PubMed for cases reported up to June 30, 2024. Clinical data from 74 patients were analyzed. Among those with severe sequelae (n = 28), 39.2% (n = 11) had hemorrhagic findings on CT or MRI, significantly more than in the mild sequelae group (10.8% [n = 5], P = 0.04). 16 patients underwent genetic testing for RANBP2 mutations, of whom four (25%, n = 16) tested positive. These findings suggest that imaging evidence of hemorrhage may be a poor prognostic factor and that RANBP2 mutations could contribute to disease susceptibility. Further genetic studies involving larger cohorts are needed to better understand the mechanisms of ANE associated with COVID-19 and improve outcomes for affected patients.
- 4 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Open AccessAcute necrotizing encephalopathy associated with COVID-19 in a pediatric patient and a systematic review
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, can lead to neurological complications such as acute necrotizing encephalopathy (ANE). However, the pathogenesis of ANE associated with COVID-19 remains unclear. We report a case of ANE associated with COVID-19 and then conducted a literature review using PubMed for cases reported up to June 30, 2024. Clinical data from 74 patients were analyzed. Among those with severe sequelae (n = 28), 39.2% (n = 11) had hemorrhagic findings on CT or MRI, significantly more than in the mild sequelae group (10.8% [n = 5], P = 0.04). 16 patients underwent genetic testing for RANBP2 mutations, of whom four (25%, n = 16) tested positive. These findings suggest that imaging evidence of hemorrhage may be a poor prognostic factor and that RANBP2 mutations could contribute to disease susceptibility. Further genetic studies involving larger cohorts are needed to better understand the mechanisms of ANE associated with COVID-19 and improve outcomes for affected patients.
- 26 June 2023
- Published by Georg Thieme Verlag KG in Journal of Pediatric Epilepsy
- Vol. 13 (01) , 001-005
Safety and Tolerability of COVID-19 Vaccination in Adolescents and Young Adults with Epilepsy: A Multicenter Questionnaire Study
Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 and was first recorded in December 2019. COVID-19 became a pandemic involving almost all countries, including Japan. We evaluated the tolerability and safety of coronavirus vaccines in terms of seizures in adolescents and young adults with epilepsy (AYAWE). Methods We administered a questionnaire to AYAWE who visited the pediatrics departments of Hiroshima University Hospital, Hiroshima Prefectural Hospital, and Hiroshima City Funairi Citizens Hospital in January and February 2022. Tolerability and safety after immunization were assessed. Results In total, 114 vaccinations were delivered to 57 AYAWE aged 12 to 25 years (mean, 15 ± 3.1 years). Fifty-two (91.2%) experienced more than or equal to 1 adverse event postvaccination. The most commonly reported adverse events were fever (dose 1, 33.3%; dose 2, 73.7%) and fatigue (dose 1, 24.6%; dose 2, 50.9%). The incidences of headache (5.2 vs. 21.0%, p = 0.024), fever (33.3 vs. 73.7%, p < 0.001), and fatigue (24.6 vs. 50.9%, p = 0.004) differed significantly between the first and second doses. Only 5.2% of patients experienced transient seizure worsening, and only one patient reported a change in seizure semiology. Conclusion COVID-19 vaccines were well-tolerated in our cohort. The vaccines did not affect the number or manifestations of seizures. Similar to other illnesses, vaccination for COVID-19 can be administered to AYAWE without worsening their seizures.
- 26 June 2023
- Published by Georg Thieme Verlag KG in Journal of Pediatric Epilepsy
- Vol. 13 (01) , 001-005
Safety and Tolerability of COVID-19 Vaccination in Adolescents and Young Adults with Epilepsy: A Multicenter Questionnaire Study
Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 and was first recorded in December 2019. COVID-19 became a pandemic involving almost all countries, including Japan. We evaluated the tolerability and safety of coronavirus vaccines in terms of seizures in adolescents and young adults with epilepsy (AYAWE). Methods We administered a questionnaire to AYAWE who visited the pediatrics departments of Hiroshima University Hospital, Hiroshima Prefectural Hospital, and Hiroshima City Funairi Citizens Hospital in January and February 2022. Tolerability and safety after immunization were assessed. Results In total, 114 vaccinations were delivered to 57 AYAWE aged 12 to 25 years (mean, 15 ± 3.1 years). Fifty-two (91.2%) experienced more than or equal to 1 adverse event postvaccination. The most commonly reported adverse events were fever (dose 1, 33.3%; dose 2, 73.7%) and fatigue (dose 1, 24.6%; dose 2, 50.9%). The incidences of headache (5.2 vs. 21.0%, p = 0.024), fever (33.3 vs. 73.7%, p < 0.001), and fatigue (24.6 vs. 50.9%, p = 0.004) differed significantly between the first and second doses. Only 5.2% of patients experienced transient seizure worsening, and only one patient reported a change in seizure semiology. Conclusion COVID-19 vaccines were well-tolerated in our cohort. The vaccines did not affect the number or manifestations of seizures. Similar to other illnesses, vaccination for COVID-19 can be administered to AYAWE without worsening their seizures.
- 6 October 2022
- Published by Elsevier in Brain and Development
- Vol. 45 (1) , 2-7
Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy
- 6 October 2022
- Published by Elsevier in Brain and Development
- Vol. 45 (1) , 2-7
Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy
- Open Access
- 20 October 2020
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 41 (1) , 125-135
IRAK4 Deficiency Presenting with Anti-NMDAR Encephalitis and HHV6 Reactivation
IRAK4 deficiency is an inborn error of immunity predisposing patients to invasive pyogenic infections. Currently, there is no established simple assay that enables precise characterization of IRAK4 mutant alleles in isolation. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune condition that is characterized by psychiatric symptoms, involuntary movement, seizures, autonomic dysfunction, and central hypoventilation. It typically occurs in adult females associated with tumors. Only a few infantile cases with anti-NMDAR encephalitis have been so far reported. We identified a 10-month-old boy with IRAK4 deficiency presenting with anti-NMDAR encephalitis and human herpes virus 6 (HHV6) reactivation. The diagnosis of IRAK4 deficiency was confirmed by the identification of compound heterozygous mutations c.29_30delAT (p.Y10Cfs*9) and c.35G>C (p.R12P) in the IRAK4 gene, low levels of IRAK4 protein expression in peripheral blood, and defective fibroblastic cell responses to TLR and IL-1 (TIR) agonist. We established a novel NF-κB reporter assay using IRAK4-null HEK293T, which enabled the precise evaluation of IRAK4 mutations. Using this system, we confirmed that both novel mutations identified in the patient are deleterious. Our study provides a new simple and reliable method to analyze IRAK4 mutant alleles. It also suggests the possible link between inborn errors of immunity and early onset anti-NMDAR encephalitis.
- 20 October 2020
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 41 (1) , 125-135
Open AccessIRAK4 Deficiency Presenting with Anti-NMDAR Encephalitis and HHV6 Reactivation
IRAK4 deficiency is an inborn error of immunity predisposing patients to invasive pyogenic infections. Currently, there is no established simple assay that enables precise characterization of IRAK4 mutant alleles in isolation. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune condition that is characterized by psychiatric symptoms, involuntary movement, seizures, autonomic dysfunction, and central hypoventilation. It typically occurs in adult females associated with tumors. Only a few infantile cases with anti-NMDAR encephalitis have been so far reported. We identified a 10-month-old boy with IRAK4 deficiency presenting with anti-NMDAR encephalitis and human herpes virus 6 (HHV6) reactivation. The diagnosis of IRAK4 deficiency was confirmed by the identification of compound heterozygous mutations c.29_30delAT (p.Y10Cfs*9) and c.35G>C (p.R12P) in the IRAK4 gene, low levels of IRAK4 protein expression in peripheral blood, and defective fibroblastic cell responses to TLR and IL-1 (TIR) agonist. We established a novel NF-κB reporter assay using IRAK4-null HEK293T, which enabled the precise evaluation of IRAK4 mutations. Using this system, we confirmed that both novel mutations identified in the patient are deleterious. Our study provides a new simple and reliable method to analyze IRAK4 mutant alleles. It also suggests the possible link between inborn errors of immunity and early onset anti-NMDAR encephalitis.
- 1 October 2019
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 38 (10) , e277
A Case in Which Oral Baclofen Was Effective for Dysphagia Associated With Acute Flaccid Myelitis by Enterovirus D68
- 1 October 2019
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 38 (10) , e277
A Case in Which Oral Baclofen Was Effective for Dysphagia Associated With Acute Flaccid Myelitis by Enterovirus D68
- 1 May 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 94, 82-86
Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy
- 1 May 2019
- Published by Elsevier in Epilepsy & Behavior
- Vol. 94, 82-86
Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy
- 2 April 2019
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 50 (03) , 160-163
High Incidence of Renal Stones in Severely Disabled Children with Epilepsy Treated with Topiramate
Purpose This study was aimed to assess the accurate incidence of renal stones in severely disabled children treated with topiramate (TPM). Method We reviewed the medical records of severely disabled children with epilepsy under 15 years old who underwent radiological examinations to investigate urinary stones. The study enrolled 26 patients who were divided into two groups. One group had been treated with TPM for at least 1 year and the other had not been treated with TPM, zonisamide, acetazolamide, or other diuretic drugs. We collected parameters from the medical records and compared the groups. Results All participants were evaluated radiologically, with computed tomography (CT) in two patients, ultrasonography in 22 patients, and both in two. No patient had any morphological abnormality of the kidneys and history of urinary tract infection. There were no significant differences in sex, age, body weight, or feeding manner between the groups, while the incidence of renal stones or calcifications was significantly higher in the TPM-treated group (60 vs. 0%; p = 0.00241). Conclusion There is a high incidence of renal stone formation in severely disabled children treated with TPM.
- 2 April 2019
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 50 (03) , 160-163
High Incidence of Renal Stones in Severely Disabled Children with Epilepsy Treated with Topiramate
Purpose This study was aimed to assess the accurate incidence of renal stones in severely disabled children treated with topiramate (TPM). Method We reviewed the medical records of severely disabled children with epilepsy under 15 years old who underwent radiological examinations to investigate urinary stones. The study enrolled 26 patients who were divided into two groups. One group had been treated with TPM for at least 1 year and the other had not been treated with TPM, zonisamide, acetazolamide, or other diuretic drugs. We collected parameters from the medical records and compared the groups. Results All participants were evaluated radiologically, with computed tomography (CT) in two patients, ultrasonography in 22 patients, and both in two. No patient had any morphological abnormality of the kidneys and history of urinary tract infection. There were no significant differences in sex, age, body weight, or feeding manner between the groups, while the incidence of renal stones or calcifications was significantly higher in the TPM-treated group (60 vs. 0%; p = 0.00241). Conclusion There is a high incidence of renal stone formation in severely disabled children treated with TPM.
- 1 November 2018
- Published by Elsevier in Brain and Development
- Vol. 40 (10) , 943-946
Anti-MOG antibody encephalitis mimicking neurological deterioration in a case of Rett syndrome with MECP2 mutation
- 1 November 2018
- Published by Elsevier in Brain and Development
- Vol. 40 (10) , 943-946
Anti-MOG antibody encephalitis mimicking neurological deterioration in a case of Rett syndrome with MECP2 mutation